Basilea's future in anti-infectives

Another Cresemba Pfizer milestone

Basilea - a year of significant achievement

CHF20m Astellas milestone

Basilea - Cresemba approved in Japan

Basilea - Sustainable profitability

Basilea - Another oncology programme partnered

Basilea - Positive data at IDweek

Basilea - Still capturing value from oncology

Basilea - Focus on anti-infectives apparent

Basilea - Dilution overhang removed

Basilea - H1 results show continued commercial and strategic progress

Diurnal Group - Trading update ahead of R&D Day

Basilea - Positive Phase 3 results

Basilea - New positioning apparent

Basilea - New territory growth

Basilea - The prospects for anti-infectives

Basilea - Boosting the anti-fungal franchise

Diurnal Group - Efmody set for Swiss launch with EffRx

Diurnal Group - European commercial roll-out continues